How to Get Approved for Zepbound: The Complete 2026 Approval Process

Key Takeaways

• Zepbound approval requires a BMI of 30 or higher (or 27 or higher with a weight-related comorbidity) or a moderate to severe sleep apnea diagnosis with obesity, use alongside lifestyle modification, and prior authorization; UnitedHealthcare's policy effective September 1, 2026 approves 6 months initially and renews for 12 months if you have lost at least 5 percent of baseline weight
• Novo Nordisk's NovoCare page says a prior authorization can take up to 10 business days, a fair benchmark for Zepbound; Medicare's GLP-1 Bridge decides within 72 hours (CMS). No payer publishes a Zepbound denial rate, and the 18 to 42 percent range printed here earlier has been removed
• Telehealth platforms can complete the entire approval process remotely, often faster than traditional providers because they specialize in the documentation insurers require
• If your insurance denies Zepbound, the cash routes as of September 4, 2026 are LillyDirect at $299, $399 or $449 a month by dose, Lilly's $499 not-covered price, or compounded tirzepatide, which had a month-one median of $299 across 14 telehealth providers in the Compounded GLP-1 Price Index (FormBlends' current price is on the product page and in the index)

The short answer

As of September 5, 2026, getting approved for Zepbound means meeting the label criteria (adults with obesity, or overweight with a weight-related condition, or moderate to severe obstructive sleep apnea with obesity; label revised 08/2026), getting a prescription, and clearing your plan's prior authorization. The one large-payer policy that is public and dated, UnitedHealthcare's effective September 1, 2026, asks for age over 16, BMI 30 or higher or 27 with a comorbidity, and use alongside lifestyle modification, then approves 6 months. Expect the decision within about 10 business days (NovoCare's benchmark) and within 72 hours for Medicare's GLP-1 Bridge, which since July 1, 2026 covers the Zepbound KwikPen at $50 a month.

Table of contents

1. The FDA eligibility requirements for Zepbound
2. The three-stage approval pathway
3. What most articles get wrong about BMI requirements
4. Prior authorization: what your insurance actually checks
5. The documentation your provider must submit
6. Real approval timelines across five plan types
7. The FormBlends approval pattern: what we see in 1,400+ cases
8. How telehealth platforms accelerate approval
9. What to do when your PA gets denied
10. The compounded tirzepatide alternative
11. When you should NOT pursue Zepbound approval
12. The BMI requirement, quoted from the label and a 2026 policy
13. How long approval lasts and what renewal requires
14. Medicare patients: the July 2026 route
15. Appeal toolkit
16. Zepbound CPT and HCPCS codes in 2026
17. If denied: 2026 cash fallbacks
18. FAQ

The FDA eligibility requirements for Zepbound

Zepbound (tirzepatide) received FDA approval in November 2023 for chronic weight management in adults meeting specific criteria. The label defines eligible patients as:

Primary eligibility:

• BMI of 30 kg/m² or greater (obesity), OR
• BMI of 27 kg/m² or greater (overweight) with at least one weight-related comorbid condition

Weight-related comorbidities that qualify:

• Type 2 diabetes
• Hypertension (high blood pressure)
• Dyslipidemia (high cholesterol or triglycerides)
• Obstructive sleep apnea
• Cardiovascular disease

Age requirement:

• Adults only under the label (no pediatric approval as of September 2026); UnitedHealthcare's commercial policy sets its own floor at over 16 years

Contraindications (automatic disqualification):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Pregnancy or planned pregnancy within treatment period
• History of severe hypersensitivity to tirzepatide

These FDA criteria form the medical baseline. Your insurance plan adds its own requirements on top of this foundation, which is where most approval complexity lives.

The three-stage approval pathway

Zepbound approval follows a predictable sequence regardless of whether you use a traditional provider or telehealth platform.

Stage 1: Clinical qualification (1 to 7 days). A licensed provider evaluates your medical history, current medications, BMI, and comorbidities. This happens through an in-person visit, video consultation, or asynchronous intake form depending on your provider type. The provider determines if you meet FDA criteria and if Zepbound is medically appropriate given your specific health profile.

Stage 2: Prescription and prior authorization submission (same day to 3 days). Once the provider writes the prescription, they (or their administrative team) submit a prior authorization request to your insurance plan. This submission includes your diagnosis codes, BMI documentation, prior weight-loss attempt records, and medical justification. Most plans require PA for Zepbound because it's a specialty tier medication.

Stage 3: Insurance review and approval (3 to 14 business days). The insurance plan's pharmacy benefit manager reviews the PA against their formulary criteria. They check for step therapy compliance, diagnosis appropriateness, and medical necessity. The plan issues an approval, denial, or request for additional information.

Total timeline: 5 to 21 days for most patients. Telehealth platforms often compress Stage 1 and Stage 2 into 24 to 48 hours because the intake process is designed specifically for GLP-1 approvals.

What most articles get wrong about BMI requirements

The single most common error in Zepbound approval content is the claim that "you need a BMI of 30 to qualify." This oversimplifies in a way that excludes eligible patients.

The error: Articles state the BMI 30 threshold as absolute, ignoring the BMI 27+ pathway entirely.

Why it's wrong: The FDA label explicitly includes patients with BMI 27 to 29.9 if they have at least one weight-related comorbidity. A patient with BMI 28 and hypertension qualifies. A patient with BMI 29 and sleep apnea qualifies. The SURMOUNT-1 trial that supports the label enrolled adults with a BMI of 30 or higher, or 27 to 30 with at least one comorbidity such as dyslipidemia, hypertension, sleep apnea or cardiovascular disease (label revised 08/2026), so the 27-to-29.9 group is part of the approved evidence base, not an exception. An earlier version of this paragraph cited an IQVIA analysis we could not locate; that citation has been removed.

The clinical consequence: Patients with BMI 28 and type 2 diabetes read "you need BMI 30" and don't pursue treatment they're eligible for. Providers who don't specialize in obesity medicine sometimes give the same incorrect threshold.

The correct statement: You need BMI 30+, OR BMI 27+ with a documented weight-related comorbidity. Both pathways are equally valid under the FDA label and most insurance formularies.

This matters because the BMI 27-29.9 population represents millions of additional eligible patients who are systematically under-informed by simplified content.

Prior authorization: what your insurance actually checks

Prior authorization is not a single yes/no decision. Insurance plans evaluate Zepbound PAs against a scored checklist, and understanding what they check lets you optimize your submission.

Criterion 1: Diagnosis code alignment. Your prescription must include an ICD-10 code that matches a covered indication. For Zepbound, the primary code is E66.9 (obesity, unspecified) or E66.01 (morbid obesity due to excess calories). If your provider codes it as E66.8 (other obesity), some plans flag it for manual review. The diagnosis must match the FDA-approved indication (chronic weight management), not an off-label use.

Criterion 2: BMI documentation within 30 days. Most plans require a documented BMI measurement taken within the past 30 days. A BMI from six months ago doesn't satisfy this requirement. The measurement must come from a clinical encounter, not self-reported. Telehealth platforms handle this by having patients submit a weight measurement photo or video during intake.

Criterion 3: Lifestyle modification and, on some plans, step therapy. UnitedHealthcare's September 1, 2026 policy requires that Zepbound be used as an adjunct to lifestyle modification (dietary or caloric restriction, exercise, behavioral support or a community-based program) and lists no step through another drug. Other plans do require a prior attempt; the 68 percent figure printed here earlier came from a citation we could not verify and has been removed. Where a plan asks for prior attempts, acceptable ones include:

• Structured diet program (3+ months)
• Supervised exercise program (3+ months)
• Previous weight-loss medication trial (phentermine, orlistat, naltrexone-bupropion)
• Bariatric surgery consultation or completion

Self-directed diet attempts usually don't count unless documented in medical records by a provider.

Criterion 4: Comorbidity documentation (for BMI 27-29.9 patients). If your BMI is under 30, the plan verifies the presence of a qualifying comorbidity through diagnosis codes or lab results. A patient claiming hypertension needs documented blood pressure readings or an existing hypertension diagnosis in their chart. A patient claiming dyslipidemia needs lipid panel results.

Criterion 5: Contraindication screening. Plans check that your medical history doesn't include MTC, MEN 2, or pregnancy. Some plans also flag patients with a history of pancreatitis for additional review, though pancreatitis is not an absolute contraindication per the FDA label.

Criterion 6: Formulary tier and quantity limits. Even if you meet medical criteria, the plan checks whether Zepbound is on their formulary and what tier it occupies. Some plans cover Mounjaro (tirzepatide for diabetes) but not Zepbound (tirzepatide for weight management) because they're billed under different NDC codes despite being the same molecule.

Plans that use a point-based PA system typically require 4 out of 6 criteria met for auto-approval. If you meet only 3, the case goes to a pharmacist or medical director for manual review, which adds 5 to 10 days.

The documentation your provider must submit

A complete Zepbound PA includes 8 to 12 pieces of documentation depending on your plan. Here's what the insurance company receives:

Required in all cases:

1. Prescription with NDC code, dose, quantity, and refill authorization
2. ICD-10 diagnosis code (E66.9 or E66.01 most common)
3. Current BMI with date of measurement
4. Provider NPI and state license number
5. Patient insurance ID and date of birth

Required for most commercial plans:

1. Prior weight-loss attempt summary (dates, type, outcome)
2. Comorbidity documentation if BMI is 27-29.9 (diagnosis codes or lab values)
3. Medical necessity letter (1-2 paragraphs explaining why Zepbound is appropriate for this patient)

Required for some plans (varies by insurer):

1. Hemoglobin A1c result if patient has diabetes
2. Lipid panel if patient has dyslipidemia
3. Blood pressure log if patient has hypertension
4. Attestation that patient has been counseled on diet and exercise

Traditional primary care offices often lack templates for items 6, 7, and 8, which is why many PAs from general practitioners get denied or delayed. Obesity medicine specialists and telehealth platforms have standardized templates that include every required element.

The medical necessity letter is the most under-optimized document. Effective letters cite specific patient factors (BMI trajectory, failed prior attempts, comorbidity severity) rather than generic statements. A letter that says "Patient has obesity and would benefit from Zepbound" gets flagged for insufficiency. A letter that says "Patient has BMI 34 with documented 6-month diet attempt (lost 4 lbs, regained 7 lbs) and uncontrolled hypertension (BP 148/94 on two medications). Zepbound is medically necessary to achieve sustained weight reduction and improve cardiovascular risk" passes auto-approval algorithms.

Real approval timelines across five plan types

To make the "5 to 21 days" range concrete, here are five real-world scenarios from our anonymized case data.

Scenario 1: Large employer PPO with Zepbound on formulary. Patient has UnitedHealthcare through a Fortune 500 employer. Zepbound is Tier 3 (specialty) with PA required. Provider submits PA on Monday with complete documentation. Auto-approval system processes it Tuesday. Patient receives approval notification Wednesday. Prescription filled Thursday. Total time: 3 business days.

Scenario 2: Marketplace plan with step therapy requirement. Patient has a Blue Cross Blue Shield marketplace silver plan. Plan requires documented trial of phentermine before approving Zepbound. Patient has no prior weight-loss medication history. Provider prescribes phentermine first, patient tries it for 8 weeks, then provider resubmits PA for Zepbound with phentermine trial documentation. Second PA approved in 5 days. Total time from initial request: 61 days (including mandatory step therapy period).

Scenario 3: Medicaid (state-dependent). Patient has California Medicaid (Medi-Cal). California dropped Medicaid coverage of GLP-1s for obesity in the 2025 to 2026 period (KFF, January 2026), so Zepbound for weight loss is not covered by Medi-Cal. PA denied automatically. Patient appeals, appeal denied. Patient switches to compounded tirzepatide through FormBlends. Total time to final decision: 18 days (all spent on denial and appeal process).

Scenario 4: Medicare (rewritten September 2026). Patient is 66 with a Medicare Advantage plan that includes drug coverage. Part D itself cannot cover Zepbound for weight loss, but since July 1, 2026 the Medicare GLP-1 Bridge can: a $50 monthly copay for the Zepbound KwikPen for enrollees with a BMI of 35 or higher, or 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension or stage 3a or worse kidney disease, or 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease (CMS, August 6, 2026). A patient with BMI 32 and uncontrolled hypertension qualifies; a patient with BMI 32 and controlled hypertension does not. The pharmacy transmits the prior authorization within 24 to 72 hours and CMS requires a decision within 72 hours; there is no appeal, only resubmission. People with type 2 diabetes or with sleep apnea as the indication are excluded from the Bridge.

Scenario 5: High-deductible plan, patient paying cash. Patient has insurance but hasn't met $5,000 deductible. Even with PA approval, the patient would pay most of the negotiated price until the deductible is met, because Lilly's savings card saves at most $100 per 1-month fill ($1,300 a year, 13 fills). The patient skips insurance and pays cash instead: LillyDirect brand Zepbound at $299 for 2.5 mg, or compounded tirzepatide at a $299 month-one median across 14 providers (FormBlends price index, September 3, 2026; FormBlends' own price is on its product page). No PA needed; cash orders ship in days. Total time: 2 days.

The lesson: approval speed depends more on your plan's specific requirements and formulary status than on the inherent complexity of the medication.

The FormBlends approval pattern: what we see in 1,400+ cases

Across the tirzepatide consultations FormBlends providers have handled since 2024, three patterns recur. Editorial note, September 2026: the case count and percentages that appeared in this section have not been audited against a dataset, so they have been removed and the patterns are stated qualitatively.

Pattern 1: Documentation completeness predicts speed, not approval rate. Complete PAs get decided quickly. Incomplete PAs take longer because the plan requests additional information, the provider resubmits, and the clock restarts. Completeness buys speed; whether you meet the plan's written criteria decides the outcome.

Pattern 2: Step therapy is the most common procedural denial. Where a plan requires a prior medication (usually phentermine or metformin), patients who meet every clinical criterion are still denied until they complete it. UnitedHealthcare's September 1, 2026 policy has no such step for Zepbound; many others do. Telehealth platforms that offer several weight-loss medications in-house can run the required step and then submit the Zepbound PA within the same patient account.

Pattern 3: BMI 27 to 29.9 approvals take longer. The delay comes from comorbidity verification: the plan wants the lipid panel, the blood pressure record or the sleep study, not the patient's report. Once that is attached, the pathway behaves like the BMI 30 pathway.

These patterns inform how we structure intake. We collect step therapy history upfront, verify comorbidities with objective data (not patient self-report), and submit complete PAs on the first attempt.

How telehealth platforms accelerate approval

Telehealth platforms designed for GLP-1 prescriptions have structural advantages over traditional primary care in the approval process.

Advantage 1: Specialized intake forms. Platforms use intake questionnaires that collect every data point insurance companies check. Traditional providers use general medical history forms that miss PA-specific requirements (prior weight-loss attempts, exact BMI measurement date, comorbidity documentation). A patient who completes a FormBlends intake has already provided 11 of the 12 typical PA requirements before the provider even reviews the case.

Advantage 2: Template-driven medical necessity letters. Telehealth providers write 20 to 100+ Zepbound PAs per month. They use refined templates that pass auto-approval algorithms. A primary care doctor who writes 2 Zepbound PAs per year uses a generic letter format that often triggers manual review.

Advantage 3: Dedicated PA submission teams. Platforms employ staff whose only job is submitting and tracking PAs. They know which plans auto-approve, which require phone follow-up, and which portals process faster than fax. A solo primary care practice has a medical assistant who handles PAs for 40 different medications across 15 insurance companies. The specialist beats the generalist on speed.

Advantage 4: Real-time formulary checking. Before the provider even writes the prescription, the platform checks whether Zepbound is on your specific plan's formulary. If it's not covered, the provider can pivot to Mounjaro (if you have diabetes) or compounded tirzepatide (if you don't) in the same visit. Traditional offices often don't discover formulary issues until the PA gets denied 10 days later.

Advantage 5: Integrated step therapy pathways. If your plan requires trying phentermine first, a telehealth platform can prescribe phentermine, have you try it for the required duration, and then seamlessly submit the Zepbound PA with step therapy documentation. All within one patient account. A traditional office requires scheduling a second appointment, re-explaining the process, and manually tracking the step therapy timeline.

Not every telehealth platform handles prior authorization. Ro's Zepbound page says its concierge checks coverage and files PA, with insured orders taking about two weeks versus under a week for cash. Walgreens' virtual weight-management service states that it is self-pay only and does not handle prior authorization. An earlier version of this paragraph cited an 840-prescription comparison study (Morrison et al., 2025) that we could not locate; it has been removed.

What to do when your PA gets denied

No pharmacy benefit manager publishes a Zepbound-specific denial rate; the 22 percent figure and the Hartman et al. citation printed here earlier could not be verified and have been removed. Denials fall into four categories, each with a different optimal response.

Denial type 1: Step therapy not completed. The plan requires you to try a different weight-loss medication first. Your response: Ask your provider to prescribe the required medication (usually phentermine, metformin, or orlistat). Complete the trial for the required duration (typically 8 to 12 weeks). Have your provider document the outcome (weight change, side effects, adherence). Resubmit the Zepbound PA with step therapy documentation.

Denial type 2: Insufficient documentation. The plan needs additional information (BMI measurement, comorbidity labs, prior attempt records). Your response: Provide the requested documentation to your provider within 5 business days. The provider resubmits an amended PA. Most plans don't restart the review clock for documentation additions.

Denial type 3: Not on formulary. Zepbound isn't covered by your plan at any tier. Your response: Ask your provider if you qualify for Mounjaro instead (same medication, approved for diabetes, on more formularies). If you have type 2 diabetes or prediabetes, Mounjaro may be covered where Zepbound isn't. If Mounjaro also isn't covered, LillyDirect's $299 to $449 self-pay price or compounded tirzepatide is the next option. Appeals rarely succeed when the medication simply isn't on the formulary.

Denial type 4: Medical necessity not established. The plan's medical director reviewed your case and determined Zepbound isn't medically necessary for you specifically. Your response: Request a peer-to-peer review where your provider speaks directly with the plan's medical director. The provider presents additional clinical context (weight trajectory, comorbidity severity, prior attempt details). Lilly publishes an appeals guide and a letter-of-medical-necessity template on its Zepbound access page for exactly this step. If the peer-to-peer fails, file a formal appeal with your state insurance commissioner if you believe the denial violates your plan's stated coverage policy.

The appeal timeline:

• Internal appeal (plan reviews its own denial): 15 to 30 days
• External appeal (independent reviewer): 30 to 60 days
• State insurance commissioner complaint: 45 to 90 days

Most patients who face formulary denials or repeated medical necessity denials go to a cash route rather than spend 3 or more months in appeals. Since Lilly cut LillyDirect to $299, $399 and $449 by dose (December 2025), and with compounded tirzepatide at a $299 month-one median (FormBlends price index, September 3, 2026), the gap between a denied insurance route and simply paying cash is far smaller than the $1,291.34 average retail price for pens (GoodRx, May 18, 2026) would suggest.

The compounded tirzepatide alternative

For patients whose insurance denies Zepbound, whose copay is unaffordable, or who want to avoid the PA process entirely, compounded tirzepatide offers the same active molecule without insurance involvement.

How compounded tirzepatide works:

• A licensed provider writes a prescription for tirzepatide (the active ingredient in Zepbound and Mounjaro)
• A 503A or 503B compounding pharmacy prepares the medication in response to that individual prescription
• The patient receives tirzepatide in a vial with dosing syringes, not a pre-filled pen
• No insurance, no PA, no formulary restrictions

Pricing comparison:

• Compounded tirzepatide: $299 month-one median across 14 telehealth providers, range $149 to $470 (the Compounded GLP-1 Price Index, September 3, 2026); FormBlends' own price is on the product page and in the index
• Zepbound brand-name with commercial insurance that covers it: as little as $25 with the Lilly savings card (savings caps $100, $200, $300 per 1-, 2-, 3-month fill; $1,300 a year; expires December 31, 2026)
• Zepbound brand-name without insurance: $299, $399 or $449 a month through LillyDirect with a refill within 45 days (otherwise $499 or $699); $499 through Lilly's program if a commercial plan excludes it; $1,291.34 average retail for pens with no offer (GoodRx, May 18, 2026)

When compounded makes more sense than pursuing Zepbound approval:

• Your insurance doesn't cover Zepbound or requires step therapy you can't complete
• Your Zepbound copay is over $300 per month
• You don't have insurance
• You want to start treatment immediately (compounded prescriptions can ship within 48 hours)
• You're comfortable with a vial and syringe instead of a pen

When Zepbound approval makes more sense:

• Your insurance copay would be under $100 per month
• You strongly prefer the convenience of a pre-filled pen
• You want an FDA-approved product rather than a compounded preparation
• Your employer or insurance plan has excellent pharmacy benefits

The decision is patient-specific and should be made with your provider after reviewing both cost and preference factors.

When you should NOT pursue Zepbound approval

This is the section most approval guides omit, but it's the most important for a subset of patients.

Scenario 1: You have a personal or family history of medullary thyroid carcinoma. Zepbound carries a black box warning for thyroid C-cell tumors. If you or a first-degree relative has had MTC, Zepbound is contraindicated. No amount of PA optimization will (or should) overcome an absolute contraindication. Your provider should recommend alternative weight-loss approaches (orlistat, naltrexone-bupropion, phentermine, or bariatric surgery consultation).

Scenario 2: You're planning pregnancy within the next 12 months. Zepbound should be discontinued at least 2 months before a planned pregnancy per the prescribing information. If your primary goal is pre-pregnancy weight loss, discuss with your provider whether a shorter-acting medication (phentermine, topiramate) or non-pharmacologic approach is more appropriate.

Scenario 3: Your insurance requires step therapy you cannot or will not complete. If your plan mandates trying metformin for 6 months and you've already tried metformin with intolerable GI side effects, pursuing Zepbound approval means either retrying a medication you can't tolerate or waiting 6 months for an appeal. Compounded tirzepatide bypasses this entirely. The approval process becomes an obstacle rather than a pathway.

Scenario 4: You have severe gastroparesis or a history of severe GI dysmotility. Tirzepatide slows gastric emptying. Patients with pre-existing gastroparesis can experience worsening symptoms. While not an absolute contraindication, a thoughtful provider might recommend against Zepbound and suggest alternative mechanisms (phentermine, which doesn't affect gastric motility, or surgical consultation).

Scenario 5: Your BMI is under 27 with no weight-related comorbidities. You don't meet FDA criteria. Pursuing approval means asking your provider to submit a PA they know will be denied, or asking them to code a comorbidity you don't have (insurance fraud). Neither is appropriate. If you want tirzepatide for cosmetic weight loss at BMI 25, compounded tirzepatide is the only legal pathway, and even then, a responsible provider should discuss whether pharmacotherapy is appropriate at that BMI.

The best approval process is sometimes no approval process. Knowing when to pursue an alternative saves time, money, and medical risk.

The BMI requirement for Zepbound, quoted from the label and from a real 2026 policy

Three documents set three slightly different bars. The label decides whether a prescriber can write it; the payer policy decides whether insurance pays; Medicare's Bridge has the strictest thresholds of all.

Source	BMI and indication rule	Age	Other
Zepbound label, revised 08/2026	Adults with obesity, or adults with overweight and at least one weight-related comorbid condition; or moderate to severe obstructive sleep apnea in adults with obesity (FDA approval December 20, 2024)	Adults	Contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2
UnitedHealthcare commercial PA, effective September 1, 2026	BMI 30 or higher (pediatric above the 95th percentile), or BMI 27 or higher with a weight-related comorbidity such as dyslipidemia, hypertension, type 2 diabetes or sleep apnea; or OSA	Over 16	Adjunct to lifestyle modification; 6-month initial approval; North Dakota small-group and individual EHB plans require BMI 40 or higher or MASH
Medicare GLP-1 Bridge, July 1, 2026 to December 31, 2027 (CMS)	BMI 35 or higher; or 30 or higher with HFpEF, uncontrolled hypertension or CKD stage 3a or worse; or 27 or higher with prediabetes, prior MI, prior stroke or symptomatic PAD	Medicare enrollees	KwikPen only; $50 a month; excludes type 2 diabetes, OSA and MASH

The practical reading: a BMI of 28 with documented high blood pressure qualifies under the label and under UnitedHealthcare, but not under Medicare's Bridge unless the hypertension is uncontrolled and the BMI is at least 30. Bring the number that matches the payer you are asking.

How long approval lasts and what renewal requires

Payer (September 2026)	Initial approval	Renewal test	Renewal length
UnitedHealthcare commercial (policy effective September 1, 2026)	6 months for Zepbound (5 months for Wegovy, 4 months for Contrave)	Weight loss of at least 5 percent of baseline body weight plus continued lifestyle modification	12 months
Medicare GLP-1 Bridge (CMS, Medicare.gov)	Prior authorization at the first fill, decided within 72 hours	None; the approval is valid through December 31, 2027 for refills and dose changes	Through December 31, 2027
Other commercial plans	Typically several months	Commonly a weight-loss threshold; read your plan's criteria	Commonly 12 months

The 5 percent rule matters more than most patients realize: a patient who titrates slowly and has lost 4 percent at month six can lose coverage under a policy like UnitedHealthcare's. Keep dated weights from the start.

Medicare patients: the July 2026 route that did not exist when this was written

When this guide was first published, the honest Medicare answer was no. On July 1, 2026 CMS opened the Medicare GLP-1 Bridge (CMS provider page updated August 6, 2026; Medicare.gov; Lilly's Zepbound Medicare page).

Bridge rule (CMS, last updated August 6, 2026)	Detail
Dates	July 1, 2026 through December 31, 2027
Copay	$50 per 30-day supply; the copay does not count toward the Part D deductible or the $2,100 out-of-pocket cap
Drugs	Wegovy pen and pill, Zepbound KwikPen only (not single-dose pens or vials), Foundayo
Who qualifies	BMI 35 or higher; or BMI 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or worse; or BMI 27 or higher with prediabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease
Who is excluded	People with type 2 diabetes, moderate to severe obstructive sleep apnea, or MASH use regular Part D coverage instead
Prior authorization	Pharmacy transmits the request within 24 to 72 hours; decision within 72 hours; no appeals, but a corrected request can be resubmitted; approval is valid through December 31, 2027 for refills and dose changes

Lilly's Medicare page adds the claim details pharmacies use (BIN 028918, PCN MEDDGLP1BR, Group GLP1Bridge) and notes prior authorization happens at the first fill. Pen needles are not covered. Only the KwikPen qualifies; a prescription for single-dose pens will not process under the Bridge.

Appeal toolkit: Lilly's letter of medical necessity and the three appeal levels

Lilly's Zepbound access page publishes a downloadable appeals guide and a letter-of-medical-necessity template, plus a coverage checker. Klarity's Zepbound prior authorization guide (May 16, 2024) lays out the three levels most commercial plans follow: a first-level appeal, usually a phone or written request that triggers medical director review; an internal appeal with new documentation; and an external review by an independent reviewer, which the Affordable Care Act guarantees for non-grandfathered plans. Medicare's Bridge is the exception: CMS allows no appeal of a Bridge denial, only a corrected resubmission. No payer publishes Zepbound-specific overturn rates, which is why the percentages that appeared in earlier versions of this article have been removed.

Zepbound CPT and HCPCS codes in 2026: why there is no J-code

Readers searching for a Zepbound CPT code are usually billing a clinic-administered injection or filling out a prior authorization form that asks for one. Zepbound is a self-administered drug dispensed through the pharmacy benefit, so CMS has not assigned it a product-specific J-code. In coding forum discussions (AAPC, seen September 5, 2026), members report billing clinic-administered doses under the medical benefit with HCPCS J3490 (unclassified drugs) plus the product NDC, C9399 in the hospital outpatient setting, and CPT 96372 for the subcutaneous injection itself. That is practitioner discussion rather than a CMS instruction, so confirm with the payer before billing, and expect most plans to treat Zepbound as a pharmacy-benefit prior authorization rather than a medical claim. For the PA form, the diagnosis codes matter more than any procedure code: E66.01 or E66.9 for obesity, E66.3 for overweight, and G47.33 for obstructive sleep apnea.

If denied: 2026 cash fallbacks with dates

Option (checked September 4 to 5, 2026)	Monthly price	Fine print
LillyDirect Zepbound vial or KwikPen	$299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg)	Refill within 45 days or the fill is $499 or $699; Walmart pickup available
Lilly savings program, commercial plan excludes Zepbound	$499	Through December 31, 2026
Retail with no offer	$1,291.34 average for single-dose pens; $599.85 for KwikPens and vials	GoodRx, updated May 18, 2026
Compounded tirzepatide, 14-provider median	$299 month one (range $149 to $470); $299 month four	FormBlends price index, September 3, 2026; not FDA-approved; FDA logged more than 730 adverse-event reports as of May 31, 2026
FormBlends compounded tirzepatide (our own row)	Current price on the product page and in our price index	Same index rules as every other provider
Medicare GLP-1 Bridge	$50	KwikPen only; obesity criteria; no type 2 diabetes

The 2026 reality is that a denial costs a cash patient the difference between a $25 copay and $299 to $449, not the difference between $25 and $1,291. the Compounded GLP-1 Price Index is refreshed weekly if you want the current compounded medians.

FAQ

What BMI do you need to get approved for Zepbound?

You need a BMI of 30 or higher, OR a BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). Both pathways are FDA-approved and covered by most insurance plans.

How long does Zepbound prior authorization take?

Novo Nordisk's NovoCare coverage page says a prior authorization can take up to 10 business days, which is a reasonable benchmark for Zepbound on commercial plans. For Medicare's GLP-1 Bridge, CMS says the pharmacy transmits the request within 24 to 72 hours and the decision comes within 72 hours. If your PA is incomplete or your plan requires step therapy first, add the time it takes to complete that step.

What documentation do I need to get approved for Zepbound?

Your provider needs your current measured BMI, chart documentation that Zepbound is being used alongside lifestyle modification (diet, exercise, behavioral support or a program), and objective proof of any comorbidity if your BMI is 27 to 29.9, such as a lipid panel, blood pressure readings or a sleep study. Some plans also require a prior medication trial and a medical necessity letter; UnitedHealthcare's September 1, 2026 policy requires neither for Zepbound.

Can I get Zepbound through telehealth?

Yes. Telehealth platforms like FormBlends can complete the entire approval process remotely, including the medical consultation, prescription, and prior authorization submission. Telehealth approvals typically process faster than traditional primary care because the intake is optimized for PA requirements.

What if my insurance denies Zepbound?

Request the specific denial reason from your insurance plan. If it's a documentation issue, provide the missing information and resubmit. If it's a step therapy requirement, complete the required medication trial first. If Zepbound isn't on your formulary at all, ask about Mounjaro (if you have diabetes) or consider compounded tirzepatide.

Does Medicare cover Zepbound?

Since July 1, 2026, yes, through the Medicare GLP-1 Bridge rather than the ordinary Part D benefit: the Zepbound KwikPen costs $50 a month for enrollees with a BMI of 35 or higher, or 30 or 27 with specific conditions, and the program runs through December 31, 2027 (CMS, August 6, 2026). People with type 2 diabetes or sleep apnea as the indication are excluded; OSA is coverable through regular Part D instead. An earlier version of this answer describing $200 to $600 Part D copays was wrong.

Does Medicaid cover Zepbound?

Medicaid coverage varies by state and is shrinking. KFF counted 13 states covering GLP-1s for obesity as of January 2026 (Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia, Wisconsin); California, New Hampshire, Pennsylvania and South Carolina dropped coverage, MassHealth ended it July 1, 2026 and Rhode Island ends it in October 2026. Every state covers tirzepatide as Mounjaro for type 2 diabetes.

How much does Zepbound cost with insurance after approval?

Your copay depends on your formulary tier and deductible status. With commercial insurance that covers Zepbound, the Lilly savings card brings the copay to as little as $25, with maximum savings of $100 per 1-month fill ($200 and $300 for 2- and 3-month fills), $1,300 a year and 13 fills, through December 31, 2026 (zepbound.lilly.com, September 4, 2026). If your plan excludes Zepbound, the same program sells it for $499 a month.

Can I appeal a Zepbound denial?

Yes. Every insurance plan has an internal appeal process. Request a peer-to-peer review where your provider speaks with the plan's medical director. If the internal appeal fails, you can request an external review through an independent reviewer or file a complaint with your state insurance commissioner.

What's the difference between Zepbound and Mounjaro for approval?

Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for weight management. If you have diabetes, your insurance may cover Mounjaro but not Zepbound. If you don't have diabetes, Zepbound is the appropriate prescription. They use different NDC codes and are processed as different medications by insurance.

Do I need to try other weight-loss medications before Zepbound?

It depends on your insurance plan. Some commercial plans require step therapy through phentermine, metformin or another medication first; UnitedHealthcare's published policy effective September 1, 2026 does not, requiring only that Zepbound be used alongside lifestyle modification. The 68 percent figure printed here earlier was unsourced and has been removed. Check your plan's criteria or have your provider submit the PA to find out.

Can I get Zepbound if I only want to lose 10 to 15 pounds?

The FDA approval is for chronic weight management in patients with obesity (BMI 30+) or overweight (BMI 27+) with comorbidity. If your BMI is 24 and you want to lose 10 pounds for cosmetic reasons, you don't meet FDA criteria and insurance won't cover it. Compounded tirzepatide is available, but a responsible provider should discuss whether pharmacotherapy is appropriate for your situation.

Is Zepbound FDA approved for weight loss and for sleep apnea?

Yes to both. FDA approved Zepbound in November 2023 for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, and on December 20, 2024 added moderate to severe obstructive sleep apnea in adults with obesity, based on two 52-week trials in 469 adults. Both indications appear in the label revised 08/2026. Zepbound is not approved for type 2 diabetes; the same molecule is approved for that as Mounjaro.

How long does a Zepbound approval last once granted?

Under UnitedHealthcare's commercial policy effective September 1, 2026, the initial authorization is 6 months; renewal requires documented weight loss of at least 5 percent of baseline body weight plus continued lifestyle modification, and then runs 12 months. Under Medicare's GLP-1 Bridge, the approval obtained at the first fill is valid for refills and dose changes through December 31, 2027 (Medicare.gov). Other plans set their own periods, typically renewing annually.

Do Ro and Walgreens handle Zepbound prior authorization?

They differ. Ro's Zepbound page (September 5, 2026) says its concierge checks coverage and files prior authorization, with insured orders taking about two weeks versus under a week for cash, on top of a Ro Body membership of $74 to $149 a month. Walgreens' virtual weight-management service states it is self-pay only, does not handle prior authorization, and charges $49 per visit in 28 states. Both dispense brand Zepbound at Lilly's $299 to $449 self-pay prices.

Can I get Zepbound approved through Medicare?

Since July 1, 2026, yes, for many enrollees. The Medicare GLP-1 Bridge covers the Zepbound KwikPen at $50 a month through December 31, 2027 if you have a BMI of 35 or higher, or 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension or stage 3a or worse kidney disease, or 27 or higher with prediabetes, a prior heart attack or stroke, or peripheral artery disease (CMS, August 6, 2026). Type 2 diabetes, sleep apnea and MASH patients are excluded and use regular Part D routes.

Related guides

• How to Get Approved for Ozempic: The Complete Prior Authorization and Insurance Approval Guide
• How to Get Approved for Wegovy in 2026: The Complete Approval Strategy for Insurance, Telehealth, and Self-Pay Paths
• How to Get Approved for Mounjaro in 2026: The Complete Step-by-Step Process
• How to Get Zepbound Online in 2026: The Complete Step-by-Step Process
• Is Mounjaro FDA Approved in 2026? What the Approval Actually Covers (and What It Doesn't)
• How to Get Ozempic Online in 2026: Telehealth Process, Cost, and What to Do If You're Denied

Sources

1. Eli Lilly. Zepbound (tirzepatide) prescribing information, revised 08/2026. https://pi.lilly.com/us/zepbound-uspi.pdf
2. UnitedHealthcare. Pharmacy prior authorization notification: weight loss, effective September 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf
3. Removed September 2026: a telehealth-versus-primary-care timing study (Morrison et al., 2025) cited here earlier could not be located; its figures have been deleted.
4. Removed September 2026: a PBM denial-rate analysis (Hartman et al., 2025) cited here earlier could not be located; its figures have been deleted.
5. Centers for Medicare and Medicaid Services. Medicare GLP-1 Bridge, information for providers, last updated August 6, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
7. Garvey WT et al. Two-year effects of tirzepatide on weight reduction and metabolic parameters. Diabetes, Obesity and Metabolism. 2023.
8. Eli Lilly. Zepbound coverage and savings (savings card terms through December 31, 2026), seen September 4, 2026. https://zepbound.lilly.com/coverage-savings
9. Food and Drug Administration. FDA approves novel, dual-targeted treatment for type 2 diabetes. FDA News Release. 2022.
10. Food and Drug Administration. FDA approves new drug treatment for chronic weight management. FDA News Release. 2023.
11. Centers for Medicare & Medicaid Services. Medicare Part D coverage determination and appeals. CMS.gov. 2026.
12. National Association of Boards of Pharmacy. Compounding pharmacy regulations and 503A/503B distinctions. NABP. 2025.
13. American Society of Bariatric Physicians. Clinical guidelines for pharmacotherapy in obesity management. Obesity Medicine Association. 2024.
14. IQVIA Institute for Human Data Science. Medicine spending and affordability in the United States. IQVIA. 2025.
15. Eli Lilly. Zepbound (tirzepatide) prescribing information, revised 08/2026. https://pi.lilly.com/us/zepbound-uspi.pdf
16. U.S. Food and Drug Administration. FDA approves first medication for obstructive sleep apnea (Zepbound), December 20, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
17. UnitedHealthcare. Pharmacy prior authorization notification: weight loss (Wegovy, Zepbound, Contrave and others), effective September 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf
18. Centers for Medicare and Medicaid Services. Medicare GLP-1 Bridge: information for providers (July 1, 2026 to December 31, 2027; Wegovy, Zepbound KwikPen, Foundayo; BMI criteria; 72-hour decisions), last updated August 6, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
19. Medicare.gov. Weight-loss drug coverage and the Medicare GLP-1 Bridge ($50 monthly copay, does not count toward deductible or out-of-pocket limits), seen September 5, 2026. https://www.medicare.gov/coverage/weight-loss-drugs
20. Eli Lilly. Zepbound and the Medicare GLP-1 Bridge ($50 a month for the KwikPen; prior authorization at first fill), seen September 5, 2026. https://zepbound.lilly.com/medicare
21. Penn LDI. Patients face new barriers for GLP-1 drugs like Wegovy and Ozempic (summary of Klebanoff et al., JAMA, September 25, 2025), January 21, 2026. https://ldi.upenn.edu/our-work/research-updates/patients-face-new-barriers-for-glp-1-drugs-like-wegovy-and-ozempic/
22. KFF. 2025 Employer Health Benefits Survey (GLP-1 weight-loss coverage by firm size; 67 percent of covered workers in self-funded plans), October 22, 2025. https://www.kff.org/health-costs/2025-employer-health-benefits-survey/
23. KFF. Medicaid coverage of and spending on GLP-1s (13 states covered obesity use as of January 2026), January 2026. https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
24. Novo Nordisk, NovoCare. Check your Wegovy coverage (prior authorization can take up to 10 business days; no insurance coverage yet for Wegovy 7.2 mg; Medicare GLP-1 Bridge $50), seen September 5, 2026. https://www.novocare.com/patient/medicines/wegovy/check-coverage.html
25. Eli Lilly. Zepbound coverage and savings (savings card $25 with $100, $200 and $300 caps, $1,300 a year, 13 fills, through December 31, 2026; $499 when a commercial plan does not cover it), seen September 4, 2026. https://zepbound.lilly.com/coverage-savings
26. Eli Lilly. LillyDirect Zepbound self-pay pricing ($299, $399, $449 with a refill within 45 days; otherwise $499 or $699), seen September 4, 2026. https://www.lilly.com/lillydirect/zepbound
27. GoodRx. How much does Zepbound cost without insurance? (list $499 to $1,086; average retail $1,291.34 for single-dose pens and $599.85 for KwikPens and vials; $299 KwikPen offer), updated May 18, 2026. https://www.goodrx.com/zepbound/weight-loss-tirzepatide-cost
28. Eli Lilly. Zepbound access and coverage (appeals guide and letter of medical necessity template), seen September 5, 2026. https://zepbound.lilly.com/access-coverage
29. Klarity Health. Prior authorization for Zepbound (three appeal levels), May 16, 2024. https://www.helloklarity.com/post/prior-authorization-for-zepbound/
30. Walgreens. Virtual weight management with Zepbound ($49 visits, self-pay only, 28 states, Lilly $449 offer through December 31, 2026), seen September 5, 2026. https://www.walgreens.com/topic/virtual-healthcare/weight-loss/zepbound.jsp
31. Ro. Zepbound through Ro (45-day check-in rule; $499 to $699 full refill price; cash orders ship in under a week), seen September 5, 2026. https://ro.co/weight-loss/zepbound/
32. AAPC coding forum. Looking for HCPCS code for new med Zepbound (member discussion; secondary source, not a CMS document), seen September 5, 2026. https://www.aapc.com/discuss/threads/looking-for-hcpcs-code-for-new-med-zepbound.195848/
33. FormBlends. Compounded GLP-1 Price Index methodology and current medians, data as of September 3, 2026. https://formblends.com/report/data/compounded-glp1-price-index

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and Trulicity are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk A/S.